Nivolumab trials for Renal Cell Carcinoma

All Nivolumab trials · All Renal Cell Carcinoma trials

Phase breakdown

Recruiting trials studying Nivolumab for Renal Cell Carcinoma

• A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
  NCT06362369 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
  NCT06265285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
  NCT07223424 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
  NCT06047379 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 7 locations

Common questions

How many trials study Nivolumab for Renal Cell Carcinoma?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.